"
Team:USTC CHINA/Project/AdvancingWork
From 2013.igem.org
| Line 87: | Line 87: | ||
<div class="atfigure" align="center" style="width:580px;font-size:14px;">Fig6. Selection on the of resistance of B.subtilis WB800N against neomycin</div> | <div class="atfigure" align="center" style="width:580px;font-size:14px;">Fig6. Selection on the of resistance of B.subtilis WB800N against neomycin</div> | ||
<div><p>We have figured it out that the best concentration of neomycin for selection use is 128mg/ml.</p></div> | <div><p>We have figured it out that the best concentration of neomycin for selection use is 128mg/ml.</p></div> | ||
| - | + | ||
<div><h2>THREE: Mice Experiment is in Progress</h2></div> | <div><h2>THREE: Mice Experiment is in Progress</h2></div> | ||
<div class="atfigure" align="center"><img src="https://static.igem.org/mediawiki/2013/2/22/DSC_0106.jpg"></br></br> | <div class="atfigure" align="center"><img src="https://static.igem.org/mediawiki/2013/2/22/DSC_0106.jpg"></br></br> | ||
| Line 97: | Line 97: | ||
<div class="atfigure" align="center"><img src="https://static.igem.org/mediawiki/2013/0/02/DSC_0109.jpg"></br></br> | <div class="atfigure" align="center"><img src="https://static.igem.org/mediawiki/2013/0/02/DSC_0109.jpg"></br></br> | ||
Fig4. Mice for our experiments</div> | Fig4. Mice for our experiments</div> | ||
| + | </div> | ||
<div style="float:right;font-size:26px;margin:20px auto 20px 0;"><a href="https://2013.igem.org/Team:USTC_CHINA/Project/FutureWork">Future Work >>></a></div> | <div style="float:right;font-size:26px;margin:20px auto 20px 0;"><a href="https://2013.igem.org/Team:USTC_CHINA/Project/FutureWork">Future Work >>></a></div> | ||
</div> | </div> | ||
Revision as of 15:37, 27 October 2013
Introduction
According to our experiment result, we have proved the secretion and expression possibility of TD1-antigen, TD1-adjuvant, and the antigenicity of TD1-antigen after transdermal process. So in the following experiments, we decided to utilize B.subtilis WB800N as engineered bacteria, plus shuttle vector pHT43 as secretion vector to build the B.subtilis secretory expression system. On top of this, we have taken advantage of different kinds of TD1-antigen, testing HBsAg, PA, Ag85b that have been applied into the market to check the universal property of TD1-antigen. Besides, reporters essential during real application have been found to realize the final circuit.
ONE: Expression of TD1-"X" in WB800N
1.Expression of TD1-GFP
2.Expression of TD1-antigen/adjuvant
In order to realize the secretory expression in B.subtilis, we inserted signal peptide between promoter and the TD1-Antigen/adjuvant sequence to secrete our recombinant protein. GFP was chosen to check the reliability of this circuit. After large amounts of experiments, GFP has finally been found via fluorescence microscope.
Then, three kinds of recombinant antigen, TD1-HBsAg, TD1-PA, TD1-Ag85b, and recombinant immunologic adjuvant were designed. The earliest successful protein TD1-LTB can not only be observed clear stripes in SDS-PAGE, but also be proved according to HPLC-MS.
TWO: Neomycin resistance of WB800N
Selection on the of resistance of B.subtilis WB800N against neomycin
As WB800N is a novel secretory expression system, most of whose parameters remain unclear, among which the chief problem is that its unique resistance against neomycin has never been quantitatively analyzed, and our work made up for this blank.
We have figured it out that the best concentration of neomycin for selection use is 128mg/ml.
THREE: Mice Experiment is in Progress
Fig1. This is where we conducted mice experiments, SPF Experiment Center
Fig2. Our lab-gown
Fig3. We were observing mice
Fig4. Mice for our experiments
